Biomea Fusion completes enrollment in Phase II COVALENT-211 diabetes trial
Biomea Fusion (BMEA) announces completion of enrollment in the COVALENT-211 Phase II trial of icovamenib in insulin-deficient Type 2 diabetes.
Story updates
11:02:37 AM UTC
SquawkNews
BMEA Biomea Fusion announces completion of enrollment in covalent-211 phase II trial of icovamenib in insulin-deficient type 2 Diabetes Biomea Fusion, - topline 26-week primary endpoint data from covalent-211 expected in Q1 2027
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.